Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection

Biomedical Chromatography

Volumn 20, Issue 2, 2006, Pages 166-172

  Higashi, Yasuhiko ^a   Kitahara, Miyuki ^a   Fujii, Youichi ^a  

^a HOKURIKU UNIVERSITY   (Japan)

Author keywords

Binding study; Dual ultraviolet detection; Haloperidol; Related compounds

Indexed keywords

ASSAYS; BODY FLUIDS; GLYCOPROTEINS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MELANIN; METABOLITES;

BINDING STUDIES; DUAL ULTRAVIOLET DETECTION; HALOPERIDOL; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN SERUM ALBUMINS; PHOSPHATE-BUFFERED SALINES; RELATED COMPOUNDS; SIMULTANEOUS ANALYSIS; ULTRA VIOLET DETECTION; ULTRAVIOLET DETECTION;

PROPIONIC ACID;

3 (4 FLUOROBENZOYL)PROPIONIC ACID; 4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE; AMITRIPTYLINE; AMOXAPINE; CARBAMAZEPINE; DESIPRAMINE; DROPERIDOL; DRUG METABOLITE; ETHOSUXIMIDE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MELANIN; NEUROLEPTIC AGENT; NORTRIPTYLINE; OROSOMUCOID; PAROXETINE; PHENYTOIN; PRIMIDONE; PROTRIPTYLINE; SERUM ALBUMIN; SPIPERONE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL PROCEDURES; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; REPRODUCIBILITY; SCHIZOPHRENIA; SEPARATION TECHNIQUE; SIDE EFFECT; ULTRAVIOLET SPECTROSCOPY;

EID: 32544435107     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.547     Document Type: Article

References (43)

1. Ablordeppey SY, Borne RF and Davis WM. Freezing action of a metabolite of haloperidol in frogs. Biochemical Pharmacology 1992; 43: 2181-2187.
2. Aubry AF. Applications of affinity chromatography to the study of drug-melanin binding interactions. Journal of Chromatography B 2002; 768: 67-74.
3. Bianchetti G and Morselli PL. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. Journal of Chromatography 1978; 153: 203-209.
4. Bock E, Weeke B and Rafaelsen OJ. Serum proteins in acutely psychotic patients. Journal of Psychiatric Research 1971; 9: 1-9.
5. Bowen WD, Moses EL, Tolentino PJ and Walker JM. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. European Journal of Pharmacology 1990; 177: 111-118.
6. Cahard C, Rop PP, Conquy T and Viala A. High-performance liquid chromatographic analysis of haloperidol and hydroxyhaloperidol in plasma after solid-phase extraction. Journal of Chromatography 1990; 532: 193-202.
7. Chiou GC, Li BH and Chiou FY. Effects of dopamine antagonists injected through vortex veins on intraocular pressure. Journal of Ocular Pharmacology 1989; 5: 281-291.
8. Clark BR, Tower BB and Rubin RT. Radioimmunoassay of haloperidol in human serum. Life Sciences 1977; 20: 319-325.
9. Creese I and Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 1977; 270: 180-182.
10. Eyles DW, Stedman TJ and Pond SM. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 1994; 116: 161-166.
11. Fang J, McKay G, Song J, Remillrd A, Li X and Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metabolism and Disposition 2001; 29: 1638-1643.
12. Forsman A and Larsson M. Metabolism of haloperidol. Current Therapeutic Research 1978; 24: 567-568.
13. Forsman A and Ohman R. Studies on serum protein binding of haloperidol. Current Therapeutic Research, Clinical.and Experimental 1977; 21: 245-255.
14. Forsman A, Martensson E, Nyberg G and Ohman R. A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients. Naunyn-Schmiedeberg's Archives of Pharmacology 1974; 286: 113-124.
15. Franklin M. Gas-chromatographic measurement of haloperidol in plasma. Clinical Chemistry 1980; 26: 1367-1368.
16. Freedberg KA, Innis RB, Creese I and Snyder SH. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sciences 1979; 24: 2467-2473.
17. Fujii T, Hatanaka K, Sato G, Yasui Y, Arimoto H and Mitsutsuka Y. Selective determination of haloperidol in human serum: surface ionization mass spectrometry and gas chromatography with surface ionization detection. Journal of Chromatography B 1996; 687: 395-403.
18. Gorrod JW and Fang J. On the metabolism of haloperidol. Xenobiotica 1993; 23: 495-508.
19. Haring N, Salama Z, Todesko L and Jaeger H. Gas chromatographic-mass spectrometric determination of haloperidol in plasma. Application to pharmacokinetics. Arzneimittel-Forschung 1987; 37: 1402-1404.
20. Ings RM. The melanin binding of drugs and its implications. Drug Metabolism Reviews 1984; 15: 1183-1212.
21. Jann MW, Crabtree BL, Pitts WM, Lam YW and Carter JG. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology 1997; 36: 32-36.
22. Jatlow PI, Miller R and Swigar M. Measurement of haloperidol in human plasma using reversed-phase high-performance liquid chromatography. Journal of Chromatography 1982; 227: 233-238.
23. Kalgutkar AS, Taylor TJ, Venkatakrishnan K and Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metabolism and Disposition 2003; 31: 243-249.
24. Kehoe WA, Kwentus JA, Sheffel WB and Harralson AF. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine. Biological Psychiatry 1991; 29: 489-493.
25. Korpi ER and Wyatt RJ. Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology 1984; 83: 34-37.
26. Kristensen S, Orsteen AL, Sande SA and Tonnesen HH. Photoreactivity of biologically active compounds. VII. Interaction of antimalarial drugs with melanin in vitro as part of phototoxicity screening. Journal of Photochemistry and Photobiology B 1994; 26: 87-95.
27. Lal S, Bloom D, Silver B, Desjardins B, Krishnan B, Thavundayil J and Thompson T. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. Journal of Psychiatry and Neuroscience 1993; 18: 173-177.
28. Leblanc B, Jezequel S, Davies T, Hanton G and Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regulatory Toxicology and Pharmacology 1998; 28: 124-132.
29. Lowrey AH, Famini GR, Loumbev V, Wilson LY and Tosk JM. Modeling drug-melanin interaction with theoretical linear solvation energy relationships. Pigment Cell Research 1997; 10: 251-256.
30. Lyden A, Larsson B and Lindquist NG. Studies on the melanin affinity of haloperidol. Archives Internationales de Pharmacodynamie et de Therapie 1982; 259: 230-243.
31. Miller RL and DeVane CL. Measurement of haloperidol and reduced haloperidol in human plasma using reversed-phase high-performance liquid chromatography. Journal of Chromatography 1986; 374: 405-408.
32. Nemeroff CB, Krishnan KR, Blazer DG, Knight DL, Benjamin D and Meyerson LR. Elevated plasma concentrations of alpha 1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Archives of General Psychiatry 1990; 47: 337-440.
33. Parkinson D. Sensitive analysis of butyrophenone neuroleptics by high-performance liquid chromatography with ultraviolet detection at 254 nm. Journal of Chromatography 1985; 341: 465-472.
34. Salazar-Bookaman MM, Wainer I and Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. Journal of Ocular Pharmacology 1994; 10: 217-239.
35. Sato H, Uematsu T, Yamada K and Nakashima M. Chlorpromazine in human scalp hair as an index of dosage history: comparison with simultaneously measured haloperidol. European Journal of Clinical Pharmacolpgy 1993; 44: 439-444.
36. Tjalve H, Nilsson M and Larsson B. Studies on the binding of chlorpromazine and chloroquine to melanin in vivo. Biochemical. Pharmacology 1981; 30: 1845-1847.
37. Van den Eeckhout E, Belpaire FM, Bogaert MG and De Moerloose P. Radioimmunoassay of bromperidol and haloperidol in human and canine plasma. European Journal of Drug Metabolism and Pharmacokinetics 1980; 5: 45-48.
38. Virno M, Gazzaniga A, Taverniti L, Pecori Giraldi J and De Gregorio F. Dopamine, dopaminergic drugs and ocular hypertension. International Ophthalmology 1992; 16: 349-353.
39. Watanabe M, Tateishi T, Tanaka M, Kumai T and Kobayashi S. Role of CYP3A in bromperidol metabolism in rat in vitro and in vivo. Xenobiotica 1999a; 29: 839-846.
40. Watanabe M, Tateishi T, Asoh M, Nakura H, Tanaka M, Kumai T and Kobayashi S. Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats. Fundamental and Clinical Pharmacology 1999b; 13: 337-342.
41. Wilhelm D and Kemper A. High-performance liquid chromatographic procedure for the determination of clozapine, haloperidol, droperidol and several benzodiazepines in plasma. Journal of Chromatography 1990; 525: 218-224.
42. Yasui-Furukori N, Inoue Y, Chiba M and Tateishi T. Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography. Journal of Chromatography B 2004a; 805: 175-180.
43. Yasui-Furukori N, Saito M, Furukori H, Inoue Y, Someya T, Kaneko S and Tateishi T. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Therapeutic Drug Monitoring 2004b; 26: 336-341.